Prograf + Methotrexate + Cyclosporine

ApprovedCompleted

0 views this week 0 watching⚡ Active

Interest: 43/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Graft Versus Host Disease

Conditions

Graft Versus Host Disease

Trial Timeline

Feb 1, 2008 → Feb 1, 2010

NCT ID

NCT02660684

About Prograf + Methotrexate + Cyclosporine

Prograf + Methotrexate + Cyclosporine is a approved stage product being developed by Astellas Pharma for Graft Versus Host Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT02660684. Target conditions include Graft Versus Host Disease.

What happened to similar drugs?

20 of 20 similar drugs in Graft Versus Host Disease were approved

Approved (20) Terminated (1) Active (0)

✅tacrolimusAstellas PharmaApproved

✅azathioprine + sirolimusAstellas PharmaApproved

✅Aspirin + TicagrelorAstraZenecaApproved

✅SugammadexMerckApproved

✅RuxolitinibNovartisApproved

✅CyclosporineNovartisApproved

✅Everolimus + Tacrolimus + Mycophenolic acidNovartisApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02660684	Approved	Completed	Feb 1, 2008	Feb 1, 2010	Graft Versus Host Disease

Competing Products

20 competing products in Graft Versus Host Disease

See all competitors

Product	Company	Stage	Hype Score
Alefacept	Astellas Pharma	Phase 2	27
tacrolimus	Astellas Pharma	Approved	43
Tacrolimus + Tacrolimus	Astellas Pharma	Pre-clinical	26
azathioprine + sirolimus	Astellas Pharma	Approved	43
Itolizumab + EQ001 Placebo	Biocon	Phase 3	32
EQ001 + EQ001 Placebo	Biocon	Phase 1/2	32
SHR0302	Jiangsu Hengrui Medicine	Phase 1	29
Acalabrutinib	AstraZeneca	Phase 2	39
Aspirin + Ticagrelor	AstraZeneca	Approved	43
Sugammadex	Merck	Approved	43
Efprezimod alfa + Methotrexate + Tacrolimus + Placebo	Merck	Phase 2	35
Ruxolitinib	Novartis	Approved	50
Imatinib Mesylate and Nilotinib	Novartis	Phase 2	35
Prednisone + Jakavi(ruxolitinib) + Prednisone	Novartis	Phase 2	42
PredEver	Novartis	Phase 2	35
Lifitegrast 5% Ophthalmic Solution + Placebo	Novartis	Phase 1	29
Cyclosporine	Novartis	Approved	39
Everolimus + Tacrolimus + Mycophenolic acid	Novartis	Approved	39
1 + 2	Novartis	Approved	43
Cyclosporine + Mycophenolate mofetil + Corticosteroids + Everolimus + Anti Thymocyte Globulin	Novartis	Approved	43